|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1994-4-21
|
|
pubmed:abstractText |
Intimal hyperplasia is induced by therapeutic vascular interventions and often results in clinically important narrowing of the vascular lumen. Examination of the role of TGF-beta 1 in a rat carotid artery injury model confirmed the presence of a previously reported increase in TGF-beta 1 mRNA in the media of injured arteries. Administration of neutralizing anti- TGF-beta 1 antibodies significantly (P < 0.05) reduced the size of the intimal lesions that developed after carotid balloon injury. A control antibody had no effect. The intimal/medial area ratio was also reduced in the anti-TGF-beta 1 group relative to controls (P < 0.01). Immunohistochemical staining showed that two TGF-beta 1-induced extracellular matrix components, EDA + fibronectin and versican, were greatly increased in the untreated neointimal lesions, but were almost completely absent from the lesions of the anti-TGF-beta 1-treated animals. We conclude that TGF-beta 1 is causally involved in the development of intimal hyperplasia, and that anti-TGF-beta 1 agents may be useful in achieving at least partial control of this condition.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1280332,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1328302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1332976,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1340215,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1371124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1425569,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1577773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1634602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1644917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1653454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1713586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1832175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1984855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-1991900,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2013155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2023924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2037600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2171777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2172262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2407884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2526131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2583089,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2663879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2734305,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-2879635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-3422628,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-3457014,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-3474655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-3475277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-3643927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-6368554,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-6876748,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-6887785,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8132757-7078457
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1172-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8132757-Animals,
pubmed-meshheading:8132757-Antibodies,
pubmed-meshheading:8132757-Base Sequence,
pubmed-meshheading:8132757-Cell Division,
pubmed-meshheading:8132757-Extracellular Matrix,
pubmed-meshheading:8132757-Hyperplasia,
pubmed-meshheading:8132757-Male,
pubmed-meshheading:8132757-Molecular Sequence Data,
pubmed-meshheading:8132757-Muscle, Smooth, Vascular,
pubmed-meshheading:8132757-Rats,
pubmed-meshheading:8132757-Rats, Sprague-Dawley,
pubmed-meshheading:8132757-Transforming Growth Factor beta
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model.
|
|
pubmed:affiliation |
Cancer Research Center, La Jolla Cancer Research Foundation, California 92037.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
